Madley Pharmaceuticals Ltd. v. Commnr of Central Excise&customs, Daman
In short. The case involves Medley Pharmaceuticals Ltd. (the appellant) appealing against the orders of the Customs Excise and Service Tax Appellate Tribunal (CESTAT) regarding the valuation of physician samples for excise duty purposes. The core issue is whether these samples should be assessed based on the cost of manufacture plus normal profits or on a pro-rata basis relative to trade packs. The Supreme Court upheld the Tribunal's decision, affirming that physician samples should be valued under the applicable rules, which the Tribunal interpreted correctly.
Facts
Medley Pharmaceuticals Ltd. filed three appeals under Section 35 L (b) of the Central Excise Act, 1944. The first appeal (Civil Appeal No. 3626 of 2005) challenges a CESTAT order confirming the Commissioner of Customs and Central Excise's decision that physician samples should be valued under Rule 4 of the Central Excise Valuation Rules, 1975. The second set of appeals (Civil Appeal Nos. 1354-1355 of 2010) contests a CESTAT ruling that upheld the Commissioner of Central Excise's determination that physician samples should be valued on a pro-rata basis for the period post-1st July 2000.
Arguments
Petitioner Arguments
The appellant argued that physician samples should not be treated as excisable goods due to their prohibition from sale under the Drugs and Cosmetics Act, 1940. They contended that the valuation should be based on the cost of manufacture plus normal profits, as per the rules applicable before 1st July 2000, and not on a pro-rata basis. The court addressed these arguments by emphasizing the legal interpretation of excise duty and the applicability of valuation rules, ultimately rejecting the notion that prohibition from sale negates excisability.
Respondent Arguments
The respondent, represented by the Commissioner of Central Excise, argued that physician samples are indeed excisable goods and should be valued based on the pro-rata method as per the rules established for trade packs. The Tribunal supported this view, stating that the prohibition on sale does not affect the capacity for valuation under excise laws. The court found the respondent's arguments compelling, as they aligned with established legal principles regarding the valuation of goods for excise purposes.
Precedents considered
The judgment referenced the case of Mayo India Ltd. and Cheryl Laboratories (P) Ltd., which established principles regarding the valuation of goods under the Central Excise Valuation Rules. The court applied these precedents to affirm that the valuation of physician samples should follow the established rules, reinforcing the Tribunal's interpretation.
Legal principles
The court considered several legal principles, including
- The definition of excisable goods under the Central Excise Act.
- The applicability of valuation rules (Rules 1975 and 2000) to determine the assessable value of goods.
- The distinction between goods that are prohibited from sale and their status as excisable goods.
Decision and reasoning
Rationale
The court reasoned that the classification of physician samples as excisable goods is consistent with the legislative framework governing excise duty. The court criticized the appellant's argument regarding the prohibition of sale, stating that such a prohibition does not exempt goods from excise duty. The court upheld the Tribunal's interpretation of the valuation rules, emphasizing the need for consistency in applying excise laws.
Outcome
The Supreme Court dismissed the appeals filed by Medley Pharmaceuticals Ltd., affirming the Tribunal's decisions. The court upheld the valuation method applied by the Commissioner and the Tribunal, confirming that physician samples are excisable goods and should be valued accordingly.
Conclusion
This judgment reinforces the legal understanding that goods, even if statutorily prohibited from sale, can still be subject to excise duty. It clarifies the application of valuation rules in determining the assessable value of such goods, thereby providing guidance for future cases involving similar issues.
Read the full judgment on the Supreme Court website (PDF)
Find the judgments that followed or distinguished it, with the paragraph relied on in each. Two answers free on WhatsApp, no signup.